Search

Your search keyword '"Pérol, M."' showing total 653 results
Start Over Author "Pérol, M."
653 results on '"Pérol, M."'

51. LBA8 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors resistance (PIONeeR): A phase Ib/IIa clinical trial targeting identified resistance pathways

Author

Tomasini, P., Cropet, C., Jeanson, A., Pérol, M., Mazieres, J., Fontaine, C., Rabeau, A., Meurer, M., Greillier, L., Le Ray, M., Laborde, L., Cohen, A., Martin, V., Roumieux, M., Monville, F., Vivier, E., Perol, D., Chabaud, S., and Barlesi, F.

Published
2024
Full Text
View/download PDF

55. 1312P Datopotamab deruxtecan (Dato-DXd) vs docetaxel (DTX) in patients (pts) with advanced nonsquamous (NSQ) non-small cell lung cancer (NSCLC) with brain metastases (mets): Results from TROPION-Lung01

Author

Pons-Tostivint, E., Okamoto, I., Sands, J., Girard, N., Cornelissen, R., Hong, M.H., Paz-Ares, L.G., Vicente Baz, D., Sugawara, S., Cobo Dols, M., Pérol, M., Mascaux, C., Kitazono, S., Hayashi, H., Lisberg, A.E., Juan Vidal, O.J., Zhang, Y., Chargualaf, M., Uema, D., and Ahn, M-J.

Published
2024
Full Text
View/download PDF

57. 1259MO Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): An open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF)

Author

Planchard, D., Mazieres, J., Mascaux, C., Guisier, F., Tomasini, P., Wislez, M., Moro-Sibilot, D., Cousin, S., Cortot, A.B., Couraud, S., Fallet, V., Guguen, C., Lagrange, A., Madroszyk Flandin, A-C., Otto, J., Pérol, M., Roch, B., Amour, E., Morin, F., and Ricordel, C.

Published
2024
Full Text
View/download PDF

58. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data

Author

Pérol, M., primary, Felip, E., additional, Dafni, U., additional, Polito, L., additional, Pal, N., additional, Tsourti, Z., additional, Ton, T.G.N., additional, Merritt, D., additional, Morris, S., additional, Stahel, R., additional, and Peters, S., additional

Published
2022
Full Text
View/download PDF

62. 193P Safety and efficacy of immmunotherapy rechallenge following a previous immune-induced interstitial lung disease

Author

Joseph, C., primary, Mazieres, J., additional, Delaunay, M., additional, Lusque, A., additional, Michot, J-M., additional, Veillon, R., additional, Wislez, M., additional, Tomasini, P., additional, Giroux-Leprieur, E., additional, Duruisseaux, M., additional, Pérol, M., additional, Decroisette, C., additional, Duchemann, B., additional, Couraud, S., additional, Milia, J., additional, Collot, S., additional, Prevot, G., additional, and Le Pavec, J., additional

Published
2022
Full Text
View/download PDF

63. Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study

Author

Ignatius Ou SH, Nishio, M, Ahn, Mj, Mok, T, Barlesi, F, Zhou, C, Felip, E, de Marinis, F, Kim, Sw, Pérol, M, Liu, G, Migliorino, Mr, Kim, Dw, Novello, S, Bearz, A, Garrido, P, Mazieres, J, Morabito, A, Lin, Hm, Yang, H, Niu, H, Zhang, P, and Kim, Es.

Subjects
anaplastic lymphoma kinase, circulating tumor DNA, non–small cell lung cancer, tumor biomarker
Published
2022

64. Effectiveness of PD-(L)1 Inhibitors Alone or in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Non-Squamous Non-Small Cell Lung Cancer (nsq-NSCLC) With PD-L1-High Expression Using Real-World Data

Author

Pérol, M. Felip, E. Dafni, U. Polito, L. Pal, N. Tsourti, Z. Ton, T. G. N. Merritt, D. Morris, S. Stahel, R. Peters, S.

Abstract

BACKGROUND: Anti-PD-(L)1 therapy alone (cancer immunotherapy [CIT]-mono) or combined with platinum-based chemotherapy (CIT-chemo) is used as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC). Our study compared clinical outcomes with CIT-mono vs CIT-chemo in the specific clinical scenario of non-squamous (Nsq)-NSCLC with a high PD-L1 expression of ≥50\% (tumor proportion score (TPS) or tumor cells (TC)). METHODS: This was a retrospective cohort study using a real-world de-identified database. Patients with metastatic Nsq-NSCLC with high PD-L1 expression initiating first-line CIT-mono or CIT-chemo between 24 October 2016 and 28 February 2019 were followed up to 28 February 2020. We compared overall survival (OS) and real-world progression-free survival (rwPFS) using Kaplan-Meier methodology. Hazard ratios (HR) were adjusted (aHR) for differences in baseline key prognostic characteristics using inverse probability of treatment weighting methodology. RESULTS: Patients with PD-L1-high Nsq-NSCLC treated with CIT-mono (n=351), were older and less often presented with de novo stage IV disease than patients treated with CIT-chemo (n=169). With a median follow-up of 19.9 months for CIT-chemo vs 23.5 months for CIT-mono, median OS and rwPFS did not differ between the two groups (median OS: CIT-chemo, 21.0 months vs CIT-mono, 22.1 months, aHR=1.03, 95\% CI 0.77-1.39, P=0.83; median rwPFS: CIT-chemo, 10.8 months vs CIT-mono, 11.5 months, aHR=1.04, 95\% CI 0.78-1.37, P=0.81). CIT-chemo showed significant and meaningful improvement in OS and rwPFS vs CIT-mono only in the never-smoker subgroup, albeit among a small sample of patients (n=50; OS HR=0.25, 95\% CI 0.07-0.83, interaction P=0.02; rwPFS HR=0.40, 95\% CI 0.17-0.95, interaction P=0.04). CONCLUSION: Except in the subgroup of never-smoker patients, sparing the chemotherapy in first-line CIT treatment does not appear to impact survival outcomes in Nsq-NSCLC patients with high PD-L1 expression.

Published
2022

68. Évaluation en vie réelle du pembrolizumab en monothérapie dans le traitement du CBNPC métastatique PD-L1-positif (TPS ≥ 50 %) en France

Author

Pérol, M., primary, Filleron, T., additional, Quantin, X., additional, Chouaid, C., additional, Audigier-Valette, C., additional, Lena, H., additional, Kaderbhai, C., additional, Chenuc, G., additional, Santorelli, M., additional, Bensimon, L., additional, Burke, T., additional, Bosquet, L., additional, Nguyen, E., additional, and Simon, G., additional

Published
2022
Full Text
View/download PDF

69. Efficacité du Pembrolizumab en première ligne de prise en charge de cancers du poumon non à petites cellules métastatiques, PDL1 ≥ 50 % avec métastases cérébrales (étude ESCKEYP – GFPC 05–2018)

Author

Descourt, R., primary, Greillier, L., additional, Pérol, M., additional, Ricordel, C., additional, Auliac, J.B., additional, Falchero, L., additional, Gervais, R., additional, Veillon, R., additional, Vieillot, S., additional, Guisier, F., additional, Marcq, M., additional, Justeau, G., additional, Bigay-Game, L., additional, Bernardi, M., additional, Fournel, P., additional, Doubre, H., additional, Pinsolle, J., additional, Amrane, K., additional, Decroisette, C., additional, and Chouaïd, C., additional

Published
2022
Full Text
View/download PDF

70. EVIDENS : première analyse par région française des données de vie réelle de la prise en charge des patients atteints d’un cancer bronchique non à petites cellules (CBNPC) traités par nivolumab

Author

Debieuvre, D., primary, Barlesi, F., additional, Dixmier, A., additional, Raspaud, C., additional, Auliac, J.B., additional, Nicolas, B., additional, Bombaron, P., additional, Moro-Sibilot, D., additional, Asselain, B., additional, Cotte, F.E., additional, Goyard, N., additional, Gauthier, E., additional, Reynaud, D., additional, Audigier-Valette, C., additional, and Pérol, M., additional

Published
2022
Full Text
View/download PDF

71. Étude de vraie vie d’utilisation du durvalumab en consolidation après radio-chimiothérapie dans les CBNPC de stade III non résécables : cohorte française de PACIFIC-R

Author

Chouaid, C., primary, Pichon, E., additional, Wislez, M., additional, Giraud, P., additional, Hilgers, W., additional, Daniel, C., additional, Pérol, M., additional, Chouahnia, K., additional, Ano, S., additional, Giaj Levra, M., additional, Correia Da Silva, C., additional, and Falchero, L., additional

Published
2022
Full Text
View/download PDF

72. Évaluation en vie réelle du pembrolizumab en monothérapie dans le CBNPC avancé PD-L1 positif (TPS ≥ 1 %) précédemment traité, en France

Author

Pérol, M., primary, Quantin, X., additional, Lena, H., additional, Filleron, T., additional, Chouaid, C., additional, Audigier Valette, C., additional, Kaderbhai, C., additional, Chenuc, G., additional, Santorelli, M., additional, Bensimon, L., additional, Burke, T., additional, Simon, G., additional, Martin, A.L., additional, Debieuvre, D., additional, Gervais, R., additional, Schott, R., additional, Carton, M., additional, Bosquet, L., additional, and Girard, N., additional

Published
2022
Full Text
View/download PDF

73. Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273]

Author

Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., and John, T.

Published
2021
Full Text
View/download PDF

74. Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer (AM-NSCLC)

Author

Cabart, M., primary, Mourey, L., additional, Girard, N., additional, Otto, J., additional, Gervais, R., additional, Madroszyk, A., additional, Chouaid, C., additional, Dubray-Longeras, P., additional, Pérol, M., additional, Hiret, S., additional, Kaderbhai, C., additional, Pichon, E., additional, Debieuvre, D., additional, Baranzelli, A., additional, Schneider, S., additional, Schott, R., additional, Pasquier, D., additional, Simon, G., additional, Martin, A.L., additional, and Cabarrou, B., additional

Published
2021
Full Text
View/download PDF

75. 109P Treatment patterns in patients with advanced non-small cell lung cancer (aNSCLC) after discontinuing an immune checkpoint inhibitor (ICI) therapy in second-line or later in Germany and France

Author

Griesinger, F., primary, Pérol, M., additional, Durand-Zaleski, I., additional, Bosquet, L., additional, Zacharias, S., additional, Calleja, A., additional, Patel, S., additional, Waldenberger, D., additional, Reynaud, D., additional, Carroll, R., additional, Daumont, M.J., additional, Penrod, J.R., additional, Lacoin, L., additional, and Chouaid, C., additional

Published
2021
Full Text
View/download PDF

77. 1200P BrigALK2 study: A multicentric real-world study evaluating brigatinib in ALK positive advanced pre-treated non-small cell lung cancers: Long-term follow-up with focus on lorlatinib efficacy after brigatinib

Author

Descourt, R., primary, Pérol, M., additional, Rousseau-Bussac, G., additional, Planchard, D., additional, Mennecier, B., additional, Wislez, M., additional, Cadranel, J., additional, Cortot, A.B., additional, Guisier, F., additional, Galland, L., additional, Do, P., additional, Schott, R., additional, Dansin, E., additional, Arrondeau, J., additional, Auliac, J.B., additional, and Chouaid, C., additional

Published
2021
Full Text
View/download PDF

78. 1842P Molecular testing in older patients treated for an advanced or metastatic non-squamous non-small cell lung cancer

Author

Lamy, T., primary, Cabarrou, B., additional, Planchard, D., additional, Quantin, X., additional, Schneider, S., additional, Bringuier, M., additional, Besse, B., additional, Pérol, M., additional, Girard, N., additional, Schott, R., additional, Chouaid, C., additional, Ricordel, C., additional, Gervais, R., additional, Debieuvre, D., additional, Audigier-Valette, C., additional, Carton, M., additional, Filleron, T., additional, Simon, G., additional, Robain, M., additional, and Baldini, C., additional

Published
2021
Full Text
View/download PDF

79. 1258P MET exon14 skipping in non-small cell lung cancer: Clinicopathological characteristics, treatments, and efficacy of crizotinib according to functional analysis: AFonMET - GFPC study

Author

Babey, H., primary, Jamme, P., additional, Gervais, R., additional, Assié, J-B., additional, Veillon, R., additional, Doubre, H., additional, Pérol, M., additional, Guisier, F., additional, Huchot, E., additional, Decroisette, C., additional, Falchero, L., additional, Chiappa, A-M., additional, André, M., additional, Cortot, A.B., additional, Chouaid, C., additional, Le Gac, G., additional, and Descourt, R., additional

Published
2021
Full Text
View/download PDF

80. LBA45 Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)

Author

Li, B.T., primary, Smit, E.F.F., additional, Goto, Y., additional, Nakagawa, K., additional, Udagawa, H., additional, Mazieres, J., additional, Nagasaka, M., additional, Bazhenova, L., additional, Saltos, A.N., additional, Felip, E., additional, Pacheco, J.M., additional, Pérol, M., additional, Paz-Ares, L., additional, Saxena, K., additional, Shiga, R., additional, Cheng, Y., additional, Acharyya, S., additional, Shahidi, J., additional, Planchard, D., additional, and Jänne, P.A., additional

Published
2021
Full Text
View/download PDF

81. 1348P Long-term survival and health-related quality of life with nivolumab for previously-treated advanced non-small cell lung cancer (NSCLC): A wide prospective French real-world study (EVIDENS)

Author

Barlesi, F., primary, Dixmier, A., additional, Debieuvre, D., additional, Raspaud, C., additional, Auliac, J.B., additional, Nicolas, B., additional, Bombaron, P., additional, Moro-Sibilot, D., additional, Audigier-Valette, C., additional, Asselain, B., additional, Dumanoir, J., additional, Cotté, F-E., additional, Allan, V., additional, Calvet, C., additional, Reynaud, D., additional, and Pérol, M., additional

Published
2021
Full Text
View/download PDF

86. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.

Author

Reck, M, Ciuleanu, T-E, Cobo, M, Schenker, M, Zurawski, B, Menezes, J, Richardet, E, Bennouna, J, Felip, E, Juan-Vidal, O, Alexandru, A, Sakai, H, Lingua, A, Reyes, F, Souquet, P-J, De Marchi, P, Martin, C, Pérol, M, Scherpereel, A, Lu, S, Paz-Ares, L, Carbone, DP, Memaj, A, Marimuthu, S, Zhang, X, Tran, P, John, T, Reck, M, Ciuleanu, T-E, Cobo, M, Schenker, M, Zurawski, B, Menezes, J, Richardet, E, Bennouna, J, Felip, E, Juan-Vidal, O, Alexandru, A, Sakai, H, Lingua, A, Reyes, F, Souquet, P-J, De Marchi, P, Martin, C, Pérol, M, Scherpereel, A, Lu, S, Paz-Ares, L, Carbone, DP, Memaj, A, Marimuthu, S, Zhang, X, Tran, P, and John, T

Abstract

BACKGROUND: To further characterize survival benefit with first-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone, we report updated data from the phase III CheckMate 9LA trial with a 2-year minimum follow-up. PATIENTS AND METHODS: Adult patients were treatment naïve, with stage IV/recurrent non-small-cell lung cancer, no known sensitizing EGFR/ALK alterations, and an Eastern Cooperative Oncology Group performance status ≤1. Patients were randomized 1 : 1 to nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with two cycles of chemotherapy, or four cycles of chemotherapy. Updated efficacy and safety outcomes are reported, along with progression-free survival (PFS) after next line of treatment (PFS2), treatment-related adverse events (TRAEs) by treatment cycle, and efficacy outcomes in patients who discontinued all treatment components in the experimental arm due to TRAEs. RESULTS: With a median follow-up of 30.7 months, nivolumab plus ipilimumab with chemotherapy continued to prolong overall survival (OS) versus chemotherapy. Median OS was 15.8 versus 11.0 months [hazard ratio 0.72 (95% confidence interval 0.61-0.86)]; 2-year OS rate was 38% versus 26%. Two-year PFS rate was 20% versus 8%. ORR was 38% versus 25%, respectively; 34% versus 12% of all responses were ongoing at 2 years. Median PFS2 was 13.9 versus 8.7 months. Improved efficacy outcomes in the experimental versus control arm were observed across most subgroups, including by programmed death-ligand 1 and histology. No new safety signals were observed; onset of grade 3/4 TRAEs was mostly observed during the first two treatment cycles in the experimental arm. In patients who discontinued all components of nivolumab plus ipilimumab with chemotherapy treatment due to TRAEs (n = 61) median OS was 27.5 months; 56% of responders had an ongoing response ≥1 year after discontinuation. CONCLUSIONS: With a 2-year minimum follow-up, nivolumab plus ipilimumab wi

Published
2021

88. LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

Author

Ahn, M-J., Lisberg, A., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo Dols, M., Pérol, M., Mascaux, C., Poddubskaya, E., Kitazono, S., Hayashi, H., Sands, J., Hall, R., Zhang, Y., Zebger-Gong, H., Uema, D., and Okamoto, I.

Published
2023
Full Text
View/download PDF

90. 147P Non-small cell lung cancer: Artificial intelligence enables the identification of survival signatures complementary to an Immunologically active gene expression signature involving previous therapies

Author

Saintigny, P., Iriso, P., Afshar, M., Attignon, V.K., Auclair, J., Boulahfa, J., Boussageon, M., Fayette, J., Foy, J-P., Karabajakian, A., Kindermans, M., Lamkhioued, M., Lantuejoul, S., Michon, L., Ortiz-Cuaran, S., Parmentier, F., Pérol, M., Swalduz, A., and Turcat, T.

Published
2023
Full Text
View/download PDF

98. 1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A

Author

Gadgeel, S.M., Mok, T.S.K., Peters, S., Nadal, E., Han, J-Y., Alatorre Alexander, J.A., Leighl, N., Sriuranpong, V., Pérol, M., Castro, G.D., de Marinis, F., Tan, D.S.W., Paul, S., Assaf, Z.J., MacLennan, M., Lohmann, T.O., Slade, M., Mathisen, M.S., Bhagawati-Prasad, V., and Dziadziuszko, R.

Published
2023
Full Text
View/download PDF

99. 1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02

Author

Li, B.T., Planchard, D., Goto, K., Smit, E.F., De Langen, J., Goto, Y., Ninomiya, K., Kubo, T., Pérol, M., Felip, E., Hayashi, H., Nakagawa, K., Shimizu, J., Nagasaka, M., Pereira, K.M.C., Taguchi, A., Ali, A., Karnoub, M., Yonemochi, R., and Jänne, P.A.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results